文献速递病毒性肝炎

持续病毒学应答作为丙型肝炎长期结局替代终点的评估

Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究纳入1078例符合IDEAL试验标准的丙肝患者,比较干扰素与直接抗病毒药物(DAA)治疗后的持续病毒学应答(SVR)与临床结局。

要点

  • SVR与24个月无事件生存改善独立相关,调整HR为0.21。
  • DAA治疗者24个月事件率1.1%,低于干扰素无应答者的3.4%。
  • 在符合IDEAL标准的患者中,DAA获得SVR率更高且临床获益与干扰素相似。

核心结论

  • 在符合IDEAL试验标准的患者中,DAA治疗更常获得SVR,且SVR带来的临床获益与干扰素治疗者相似。
  • 尽管疾病严重程度相似,DAA治疗者事件率低于干扰素无应答者,证实SVR改变预后并改善临床结局。

研究设计与样本

  • 采用IDEAL试验标准确定干扰素资格以控制疾病严重程度。
  • 共1078例符合IDEAL标准的患者,发生1306次治疗(52%干扰素,49%DAA)。

主要发现

  • DAA组肝硬化比例为30%,干扰素组为21%(P < .001)。
  • DAA组SVR率为97%,干扰素组为52%(P < .0001)。
  • SVR者24个月累积无事件生存率:干扰素组99%,DAA组97%(P = .08);非SVR者分别为96%和75%(P = .01)。
  • 采用逆概率治疗加权匹配干扰素无应答者与DAA治疗患者,24个月事件率DAA组为1.1%,干扰素无应答组为3.4%(P = .005)。

临床怎么用

  • SVR可作为丙肝长期临床结局的可靠替代终点,支持将实现SVR作为治疗目标。
  • DAA治疗提高SVR率并转化为临床事件减少,支持在符合干扰素资格患者中优先使用DAA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The causal link of sustained virologic response (SVR) with outcome has been challenged. With improved SVR rates with direct-acting antivirals (DAAs), the benefit of SVR would be expected to diminish if the association with outcome is not causal. METHODS: Data were collected for patients starting treatment with interferon (IFN) or DAAs between June 2006 and December 2016. To control for disease severity, criteria for the IDEAL (Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy) trial determined IFN-eligibility. Clinical events were decompensation, hepatocellular carcinoma, liver transplantation, and all-cause mortality. RESULTS: In 1078 IDEAL-eligible patients, 1306 treatments occurred (52% IFN, 49% DAAs). Cirrhosis was present in 30% DAAs vs 21% IFN (P < .001). SVR was 97% with DAAs vs 52% with IFN (P < .0001). The 24-month cumulative event-free survival was 99% for IFN and 97% for DAAs with SVR (P = .08) and 96% and 75%, respectively, for non-SVR (P = .01). SVR was associated with improved event-free survival with an adjusted hazard ratio of 0.21 (95% confidence interval, .06-.71; P = .01). Using inverse probability of treatment weighting to match IFN nonresponders with DAA-treated patients, the 24-month event-rate was 1.1% with DAAs compared to 3.4% in IFN nonresponders (P = .005), highlighting the clinical benefit of maximizing SVR. CONCLUSIONS: In IFN-eligible patients, SVR is more commonly achieved with DAAs and confers a similar clinical benefit as in those treated with IFN. The reduced event-rate with DAAs compared to IFN, despite similar disease severity, confirm that SVR alters prognosis leading to improved clinical outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Krassenburg LAP, Zanjir WR, Georgie F, et al. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis. 2021. PMID: 32052014. doi:10.1093/cid/ciaa144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。